A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity

  • J Biol Chem. 2000 Jun 23;275(25):19167-76. doi: 10.1074/jbc.M910228199.
Y Shi  1 ,  S J Ullrich ,  J Zhang ,  K Connolly ,  K J Grzegorzewski ,  M C Barber ,  W Wang ,  K Wathen ,  V Hodge ,  C L Fisher ,  H Olsen ,  S M Ruben ,  I Knyazev ,  Y H Cho ,  V Kao ,  K A Wilkinson ,  J A Carrell ,  R Ebner
Affiliations
  • 1. Departments of Molecular Biology, Protein Development, Strategic Drug Development, and Cell Biology, Human Genome Sciences, Inc., Rockville, Maryland 20850, USA.
Abstract

As part of a large scale effort to discover novel secreted proteins, a cDNA encoding a novel cytokine was identified. Alignments of the sequence of the new protein, designated IL-17B, suggest it to be a homolog of the recently described T cell-derived cytokine, IL-17. By Northern analysis, EST distribution and real-time quantitative polymerase chain reaction analysis, mRNA was detected in many cell types. A novel type I transmembrane protein, identified in an EST data base by homology to IL-17R, was found to bind specifically IL-17B, as determined by surface plasmon resonance analysis, flow cytometry, and co-immunoprecipitation experiments. Readily detectable transcription of IL-17BR was restricted to human kidney, Pancreas, liver, brain, and intestines and only a few of the many cell lines tested. By using a rodent ortholog of IL-17BR as a probe, IL-17BR message was found to be drastically up-regulated during intestinal inflammation elicited by indomethacin treatment in rats. In addition, intraperitoneal injection of IL-17B purified from Chinese hamster ovary cells caused marked neutrophil migration in normal mice, in a specific and dose-dependent manner. Together these results suggest that IL-17B may be a novel proinflammatory cytokine acting on a restricted set of target cell types. They also demonstrate the strength of genomic approaches in the unraveling of novel biological pathways.